Moderna Inc has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically designed to target the Omicron coronavirus variant, a day after rival Pfizer Inc (PFE.N) launched a similar trial.The company said on Wednesday that while a third shot of its original coronavirus vaccine increased neutralising antibodies against the variant at the lower dose, their levels declined six months after the booster dose was administered.However, neutralising antibodies remained detectable in all participants, Moderna said.
Load More
Load More